Jon Wigginton MD Receives SITC Visionary Legacy Award Jon Wigginton MD Receives SITC Visionary Legacy Award
CAMBRIDGE, Mass. – November 13, 2020 – Cullinan Oncology is proud to announce that its Chief Medical Officer, Jon Wigginton MD, has been honored by the Society for Immunotherapy of Cancer (SITC) as a recipient of its 2020 Visionary Legacy Award.
This nominated award honors SITC members who are visionaries in the field of cancer immunotherapy and continue to show extraordinary ingenuity with continuous contributions in support of improving cancer patient outcomes.
“Jon has dedicated his life to improving the lives of those living with cancer, and this award recognizes his many contributions to the Society and the broader field of cancer immunotherapy. We are fortunate to have his knowledge, expertise and leadership at Cullinan as we work to develop the next breakthroughs for patients,” said Owen Hughes, CEO at Cullinan Oncology.
In addition to his role as the Chief Medical Officer at Cullinan, Jon is also an advisor at MPM Capital, a leading venture capital firm located in Cambridge, MA and several biotechnology companies. Jon served previously as President of the Society for Immunotherapy of Cancer, and he led multiple SITC programmatic initiatives.
About the SITC Visionary Legacy Award
The Visionary Legacy Award honors SITC members who are visionaries in the field and continue to show extraordinary ingenuity with continuous contributions in support of advancing the mission of the Society. Recipients of this award have helped strengthen SITC’s role in advancing the science and application of cancer immunotherapy and have demonstrated their dedication to the Society and to the field with a distinguished record of service in leadership and/or committee roles. They are leaders whose counsel others seek and who selflessly give their time and talent. They have been forward thinking during course-changing events, and their engagement has reflected a pivotal influence on the direction of the Society.
About Cullinan Oncology, LLC
Cullinan Oncology was formed to develop a diversified portfolio of highly promising single asset oncology opportunities through both internal and external means and to do so in a unique, cost-efficient model that leverages a central management team and shared services model to drive speed and efficiency. For additional information, please visit www.cullinanoncology.com.
Contact: Matt Burke, email@example.com, +1 603.315.0618